CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials
DOI 10.1055/s-0044-1789703
Bibliografische Angaben
Nachweis in CareLit
Autor:innenE. Sonnenberg, C. W Lees, F. Baert, C. Piperni, J. Wu, A. Bhattacharjee, K. Wosik, J. K Marshall
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe09/2024
Jahrgang / SeitenJg. 62 · S. e607-e608
Kernaussage aus der Literatur
Abstract-Vorschau
Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials
Zitieren
Zitierempfehlung
E. Sonnenberg, C. W Lees, F. Baert, C. Piperni, J. Wu, A. Bhattacharjee, K. Wosik, J. K Marshall (2024) Efficacy and safety of etrasimod as a first-line advanced treatment following 5-aminosalicylic acid and/or thiopurines: data from the ELEVATE UC 52 and ELEVATE UC 12 phase 3 clinical trials. Zeitschrift für Gastroenterologie, 62 (09), e607-e608. https://doi.org/10.1055/s-0044-1789703
Mit CareLit weiterarbeiten